Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation

StatusRecruiting
PhaseEarly Phase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 11 months later Dec 2028 → Dec 2030
See other at-risk trials from Massachusetts General Hospital

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Dec 2028 to Dec 2030 Show 5 more changesShow less
    • Recruitment opened
    • Study completion pushed from Dec 2029 to Dec 2031
    • Start date changed from estimate of Jul 2026 to Feb 4, 2026
    • Eligibility criteria expanded, about 24 words
    • Site details revised
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
The primary objective is to assess the safety of the addition of venetoclax to reduced intensity conditioning for HLA-matched and haploidentical combined HSC and kidney transplantation as measured by stable full donor hematopoiesis and absence of CTCAE grade IV or V toxicity attributable to venetoclax.
Trial Details
NCT Number NCT07358195
Lead Sponsor Massachusetts General Hospital
Conditions
(from sponsor)		 Kidney Failure Chronic, Stem Cell Transplant, Stem Cell Transplant Complications, Tolerance, Hematologic Cancer
Related terms Hematologic Neoplasms, Renal Insufficiency, Chronic
Enrollment 3 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov